Ipca was awarded by 'Indian Drug Manufacturers Association (IDMA) Best Formulation Patent (2014-15)' for its formulation patent of Hydroxychloroquine and its combinations in treatment of Diabetes Mellitus at 54th IDMA annual day celebration held on 23rd January 2016.
Clinical Study entitled "Efficacy and Safety of Fixed Dose Combination of Atorvastatin and Hydroxychloroquine: A Randomized, double-blind comparison with Atorvastatin Alone among Indian Patients with Dyslipidemia" is published in Current Medical Research and opinion. With this publication, Ipca's total number of publications (Including clinical and preclinical studies) has reached 37.
Clinical trial entitled "Efficacy of Low-Dose Chlorthalidone and Hydrochlorothiazide as Assessed by 24-h Ambulatory Blood Pressure Monitoring" published in renowned Journal of the American College of Cardiology. With this publication, Ipca's total number of publications has reached an impressive number 38!
Journal of the American College of Cardiology is best read, one of the most highly cited and influential cardiovascular journal worldwide, with an international reputation for excellence and a notable impact factor of 16.503. Dr. Franz Messerli, a leading authority on hypertension management is a co-author for this paper.
Ipca Laboratories wins the 'Clinical Trial result of the year' at the first annual CARE Award held at Boston, USA on 27th April 2016.
Both the entries, 'Efficacy and Safety of Fixed-Dose Combination of Atorvastatin and Hydroxychloroquine' and, 'Efficacy of Low-Dose Chlorthalidone and Hydrochlorothiazide as assessed by 24-h Ambulatory Blood Pressure Monitoring' have been nominated for this award.
Ipca was the only Indian company to get shortlisted as finalist for this prestigious awards and the only company with two projects being shortlisted in single category.
Ipca Laboratories has been conferred with "Intellectual Property (IP) Excellence Award 2016" for adopting "The Best Practices in IP Intelligence" in a function organized in Mumbai on November 28th, 2016.
The award has been granted by Questel-de Sciene Infoware in recognition of Ipca's IP intelligence analytics capabilities in an event chaired by diversified IP professionals from Leading Pharma and Biotech companies, Automobiles industry, Infrastructure, Healthcare, Textiles and Engineering Sector.
Questel-de Sciene Infoware is a French company which provides comprehensive suite of web-based services for productivity and collaboration dedicated to intellectual property. Questel has conducted India wide online survey and selected Ipca as one of the leading companies for following best practices in IP intelligence.